Recent advancements in targeted therapy for HCC, such as application of vascular endothelial growth factor receptor (VEGFR) inhibitors and programmed cell death 1 ligand 1(PD-L1) inhibitors, have sparked newfound hope [5,6]. Here, CD274 is linked to hepatocellular carcinoma.